The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression
Open accessAbstract
Early detection is critical in prevention and treatment of kidney disease. However currently clinical laboratory and histopathological tests do not provide region-specific and accurate biomarkers for early detection of kidney disease. The present study was conducted to identify sensitive biomarkers for early detection and progression of tubulo-interstitial nephropathy in aristolochic acid I-induced rats at weeks 4, 8 and 12. Biomarkers were validated using aristolochic acid nephropathy (AAN) rats at week 24, adenine-induced chronic kidney disease (CKD) rats and CKD patients. Compared with control rats, AAN rats showed anemia, increased serum urea and creatinine, progressive renal interstitial fibrosis, activation of nuclear factor-kappa B, and up-regulation of pro-inflammatory, pro-oxidant, and pro-fibrotic proteins at weeks 8 and 12. However, no significant difference was found at week 4. Metabolomics identified 12-ketodeoxycholic acid, taurochenodesoxycholic acid, LPC(15:0) and docosahexaenoic acid as biomarkers for early detection of tubulo-interstitial nephropathy. With prolonging aristolochic acid I exposure, LPE(20:2), cholic acid, chenodeoxycholic acid and LPC(17:0) were identified as biomarkers for progression from early to advanced AAN and lysoPE(22:5), indoxyl sulfate, uric acid and creatinine as biomarkers of advanced AAN. These biomarkers were reversed by treatment of irbesartan and ergone in AAN rats at week 24 and adenine-induced CKD rats. In addition, these biomarkers were also reversed by irbesartan treatment in CKD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease alters intestinal microbial flora
Vaziri, N. D., Wong, J., Pahl, M., Piceno, Y. M., Yuan, J., DeSantis, T. Z., Ni, Z., Nguyen, T.-H., & Andersen, G. L. (2013) · Kidney International · doi:10.1038/ki.2012.345 · Cited by 1,164
Self-citationKieffer, D. A., Piccolo, B. D., Vaziri, N. D., Liu, S., Lau, W. L., Khazaeli, M., Nazertehrani, S., Moore, M. E., Marco, M. L., Martin, R. J., et al. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00513.2015 · Cited by 308
Self-citationPosada-Ayala, M., Zubiri, I., Martin-Lorenzo, M., Sanz-Maroto, A., Molero, D., Gonzalez-Calero, L., Fernandez-Fernandez, B., de la Cuesta, F., Laborde, C. M., Barderas, M. G., et al. (2014) · Kidney International · doi:10.1038/ki.2013.328 · Cited by 167
Cited by
Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease
Chen, Y.-Y., Chen, D.-Q., Chen, L., Liu, J.-R., Vaziri, N. D., Guo, Y., & Zhao, Y.-Y. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-018-1756-4 · Cited by 431
Self-citationChen, L., Yang, T., Lu, D.-W., Zhao, H., Feng, Y.-L., Chen, H., Chen, D.-Q., Vaziri, N. D., & Zhao, Y.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.090 · Cited by 359
Self-citationMetabolomics for clinical use and research in chronic kidney disease
Hocher, B., & Adamski, J. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.30 · Cited by 339
Metadata
- Authors
- Chen, H., Cao, G., Chen, D.-Q., Wang, M., Vaziri, N. D., Zhang, Z.-H., Mao, J.-R., Bai, X., & Zhao, Y.-Y.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 10
- Pages
- 168-178
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W2524261334
- Cited by
- 162
- References
- 3
- FWCI
- 20.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. https://app.cochat.ai/papers/10.1016/j.redox.2016.09.014
- The paper
- Chen, H., Cao, G., Chen, D.-Q., Wang, M., Vaziri, N. D., Zhang, Z.-H., Mao, J.-R., Bai, X., & Zhao, Y.-Y. (2016). Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biology. https://doi.org/10.1016/j.redox.2016.09.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.